Brief: Vincerx Pharma Reports Fourth Quarter And Full Year 2022 Financial Results And Provides A Corporate Update
28/03/2023 23:36
March 28 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
* VINCERX PHARMA INC - EXPECTED CASH RUNWAY INTO LATE 2024
* VINCERX PHARMA INC - IND FILING FOR ANTIBODY DRUG
CONJUGATE
(ADC) VIP943 REMAINS ON TRACK FOR MID-2023
* VINCERX PHARMA INC - VIP943 EXPECTED TO BE IN CLINIC IN
SECOND
HALF 2023
* VINCERX PHARMA INC- QTRLY LOSS PER SHARE $0.65
Source text for Eikon: ID:nGNX7BMqwL
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign